End-Stage Liver Disease

Insurance status was independently associated with acute-on-chronic liver failure in patients with cirrhosis in an analysis of data from North America published in Clinical Gastroenterology and Hepatology.

Changes in diet and microbiota were linked with minimal hepatic encephalopathy and hospitalizations in patients with cirrhosis from Mexico compared with American patients, according to research published in Liver International.

Health-related quality of life scores may be useful prognostic screening tools for patients with cirrhosis, according to research published in The American Journal of Gastroenterology.

Poxel announced positive safety, tolerability and pharmacokinetic results from a phase 1b multiple ascending dose trial of PXL065, a deuterium-stabilized R-stereoisomer of Actos under investigation for nonalcoholic steatohepatitis, according to a press release.

Vanderbilt University Medical Center announced the launch of a living liver donor transplant program that will allow patients’ relatives to donate liver grafts, according to a press release.

BOSTON — In this exclusive video from The Liver Meeting 2019, Rosemary Wickowski, co-founder and chief operating officer of the Fatty Liver Foundation, addresses the liver disease community regarding the optimistic future for patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

BOSTON — A machine learning approach demonstrated a relatively high sensitivity rate for predicting the probability of non-alcoholic steatohepatitis in at-risk patients, according to data presented at The Liver Meeting 2019.

SAN ANTONIO – Though 72% of patients with cirrhosis report poor quality of life, only a third receive referral to palliative care, according to an expert at the National Liver Conference 2019.

Frailty correlated with a twofold higher risk for waitlist mortality among both patients with and without obesity in need of liver transplantation, which increased to a threefold higher risk in those with class 2 or higher obesity, according to a study published in JAMA Surgery.

Results from an extension study of the PREVAIL trial showed that hepatitis C virus reinfection rates were low among people who inject drugs on opioid agonist therapy and higher among those reporting ongoing injection drug use, or IDU.